

Hubert Schrezenmeier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7766199/publications.pdf>

Version: 2024-02-01

279
papers

15,944
citations

17440

63
h-index

19747

117
g-index

291
all docs

291
docs citations

291
times ranked

18848
citing authors

#	ARTICLE	IF	CITATIONS
1	The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. <i>New England Journal of Medicine</i> , 2006, 355, 1233-1243.	27.0	1,060
2	SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. <i>Cell</i> , 2021, 184, 2384-2393.e12.	28.9	848
3	Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2008, 111, 1840-1847.	1.4	534
4	Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2007, 110, 4123-4128.	1.4	481
5	Cdc42 Activity Regulates Hematopoietic Stem Cell Aging and Rejuvenation. <i>Cell Stem Cell</i> , 2012, 10, 520-530.	11.1	438
6	Treatment of Aplastic Anemia with Antilymphocyte Globulin and Methylprednisolone with or without Cyclosporine. <i>New England Journal of Medicine</i> , 1991, 324, 1297-1304.	27.0	406
7	Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2013, 162, 62-73.	2.5	320
8	Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2007, 92, 11-18.	3.5	318
9	Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. <i>Blood</i> , 2003, 101, 1236-1242.	1.4	298
10	A Differentiation Checkpoint Limits Hematopoietic Stem Cell Self-Renewal in Response to DNA Damage. <i>Cell</i> , 2012, 148, 1001-1014.	28.9	296
11	Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. <i>Biomaterials</i> , 2006, 27, 2820-2828.	11.4	279
12	Interleukin 21-Induced Granzyme Expressing B Cells Infiltrate Tumors and Regulate T Cells. <i>Cancer Research</i> , 2013, 73, 2468-2479.	0.9	277
13	Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. <i>Blood</i> , 2007, 110, 1397-1400.	1.4	260
14	Uptake Mechanism of Oppositely Charged Fluorescent Nanoparticles in HeLa Cells. <i>Macromolecular Bioscience</i> , 2008, 8, 1135-1143.	4.1	256
15	Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. <i>Cytotherapy</i> , 2012, 14, 540-554.	0.7	246
16	Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. <i>Blood</i> , 2019, 133, 530-539.	1.4	227
17	Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy-the European group for blood and marrow transplantation experience. <i>Seminars in Hematology</i> , 2000, 37, 69-80.	3.4	223
18	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. <i>Science Immunology</i> , 2021, 6, eabj1031.	11.9	223

#	ARTICLE	IF	CITATIONS
19	Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	212
20	Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>New England Journal of Medicine</i> , 2015, 373, 1032-1039.	27.0	201
21	Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. <i>Haematologica</i> , 2014, 99, 922-929.	3.5	195
22	TSG-6 Released from Intradermally Injected Mesenchymal Stem Cells Accelerates Wound Healing and Reduces Tissue Fibrosis in Murine Full-Thickness Skin Wounds. <i>Journal of Investigative Dermatology</i> , 2014, 134, 526-537.	0.7	195
23	A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2011, 117, 4434-4441.	1.4	187
24	Clinical-Grade Mesenchymal Stromal Cells Produced Under Various Good Manufacturing Practice Processes Differ in Their Immunomodulatory Properties: Standardization of Immune Quality Controls. <i>Stem Cells and Development</i> , 2013, 22, 1789-1801.	2.1	186
25	Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. <i>Haematologica</i> , 2012, 97, 1142-1148.	3.5	167
26	Deficiency of Innate and Acquired Immunity Caused by an <i>IKBKB</i> Mutation. <i>New England Journal of Medicine</i> , 2013, 369, 2504-2514.	27.0	161
27	Treatment of acquired aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy [mdash] The European Group for Blood and Marrow Transplantation Experience. <i>Seminars in Hematology</i> , 2000, 37, 69-80.	3.4	160
28	Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. <i>Blood</i> , 2012, 119, 5391-5396.	1.4	156
29	GMP-Compliant Isolation and Large-Scale Expansion of Bone Marrow-Derived MSC. <i>PLoS ONE</i> , 2012, 7, e43255.	2.5	156
30	Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. <i>Transfusion</i> , 2007, 47, 644-652.	1.6	155
31	Similar outcome of upfront unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2015, 171, 585-594.	2.5	146
32	Telomerase gene mutations are associated with cirrhosis formation. <i>Hepatology</i> , 2011, 53, 1608-1617.	7.3	143
33	Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. <i>Haematologica</i> , 2010, 95, 2119-2125.	3.5	137
34	Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change. <i>Journal of Clinical Oncology</i> , 2013, 31, 3259-3271.	1.6	137
35	Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial. <i>Stem Cell Research and Therapy</i> , 2018, 9, 213.	5.5	132
36	Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses. <i>Nature Nanotechnology</i> , 2013, 8, 130-136.	31.5	125

#	ARTICLE	IF	CITATIONS
37	Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. <i>Blood</i> , 2017, 129, 970-980.	1.4	119
38	Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. <i>Cytotherapy</i> , 2015, 17, 128-139.	0.7	118
39	GMP-Compliant Isolation and Expansion of Bone Marrow-Derived MSCs in the Closed, Automated Device Quantum Cell Expansion System. <i>Cell Transplantation</i> , 2013, 22, 1981-2000.	2.5	115
40	Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2007, 109, 2794-2796.	1.4	111
41	Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , 2012, 97, 1666-1673.	3.5	110
42	Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. <i>British Journal of Haematology</i> , 2015, 169, 565-573.	2.5	104
43	Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. <i>EBioMedicine</i> , 2022, 75, 103761.	6.1	104
44	Results of Intracoronary Stem Cell Therapy After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2010, 105, 804-812.	1.6	102
45	Pre-clinical studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate. <i>Stem Cell Research and Therapy</i> , 2014, 5, 114.	5.5	100
46	T lymphocyte activation by staphylococcal enterotoxins: Role of class II molecules and T cell surface structures. <i>Cellular Immunology</i> , 1989, 120, 92-101.	3.0	96
47	Eosinophils Oxidize Damage-Associated Molecular Pattern Molecules Derived from Stressed Cells. <i>Journal of Immunology</i> , 2009, 183, 5023-5031.	0.8	96
48	Phenotypic Characterization of Mesenchymal Stem Cells from Various Tissues. <i>Transfusion Medicine and Hemotherapy</i> , 2008, 35, 168-184.	1.6	94
49	Synthesis and biomedical applications of functionalized fluorescent and magnetic dual reporter nanoparticles as obtained in the miniemulsion process. <i>Journal of Physics Condensed Matter</i> , 2006, 18, S2581-S2594.	1.8	89
50	Feasibility and safety of treating non-unions in tibia, femur and humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial. <i>Biomaterials</i> , 2019, 196, 100-108.	11.4	87
51	Human B cells differentiate into granzyme B-secreting cytotoxic B lymphocytes upon incomplete T-cell help. <i>Immunology and Cell Biology</i> , 2012, 90, 457-467.	2.3	82
52	B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3027-3033.	6.1	82
53	Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. <i>British Journal of Haematology</i> , 2009, 144, 933-945.	2.5	80
54	Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , 2020, 106, 230-237.	3.5	77

#	ARTICLE	IF	CITATIONS
55	Anticoagulant-induced Pseudothrombocytopenia and Pseudoleucocytosis. <i>Thrombosis and Haemostasis</i> , 1995, 73, 506-513.	3.4	75
56	Drug induced immune haemolytic anaemia in the Berlin Caseâ€Control Surveillance Study. <i>British Journal of Haematology</i> , 2011, 154, 644-653.	2.5	75
57	Outcome of Pregnancy and Disease Course among Women with Aplastic Anemia Treated with Immunosuppression. <i>Annals of Internal Medicine</i> , 2002, 137, 164.	3.9	74
58	Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. <i>Blood Advances</i> , 2018, 2, 2543-2549.	5.2	74
59	Clonal analysis of human T cell activation by the Mycoplasma arthritis mitogen (MAS). <i>European Journal of Immunology</i> , 1988, 18, 1733-1738.	2.9	73
60	Influence of Donor/Recipient Sex Matching on Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. <i>Transplantation</i> , 2006, 82, 218-226.	1.0	73
61	Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014, 99, 1574-1581.	3.5	73
62	The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2020, 135, 912-920.	1.4	73
63	Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	72
64	The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot. <i>Blood</i> , 2003, 101, 2833-2841.	1.4	71
65	Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. <i>Blood Advances</i> , 2018, 2, 2176-2185.	5.2	65
66	Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and singleâ€lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. <i>British Journal of Haematology</i> , 2010, 148, 791-796.	2.5	63
67	Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. <i>Annals of Hematology</i> , 2020, 99, 1505-1514.	1.8	63
68	Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccinationâ€™specific humoral and cellular immunity in kidney transplant recipients. <i>JCI Insight</i> , 2022, 7, .	5.0	62
69	Drug-induced immune thrombocytopenia: results from the Berlin Caseâ€Control Surveillance Study. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 821-832.	1.9	59
70	Cerebral Ischemic Infarction in Paroxysmal Nocturnal Hemoglobinuria. <i>Journal of Neurology</i> , 2005, 252, 1379-1386.	3.6	58
71	Screening of platelet concentrates for bacterial contamination: spectrum of bacteria detected, proportion of transfused units, and clinical follow-up. <i>Annals of Hematology</i> , 2010, 89, 83-91.	1.8	57
72	Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material. <i>European Journal of Immunology</i> , 2011, 41, 2021-2028.	2.9	57

#	ARTICLE	IF	CITATIONS
73	CD4+ T Cellâ€‘Derived IL-21 and Deprivation of CD40 Signaling Favor the In Vivo Development of Granzyme Bâ€‘Expressing Regulatory B Cells in HIV Patients. <i>Journal of Immunology</i> , 2015, 194, 3768-3777.	0.8	57
74	Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. <i>Oncogene</i> , 2005, 24, 2421-2429.	5.9	56
75	Targeted Therapy with Eculizumab for Inherited CD59 Deficiency. <i>New England Journal of Medicine</i> , 2014, 370, 90-92.	27.0	55
76	Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity. <i>Blood</i> , 2021, 137, 443-455.	1.4	55
77	B Cell Numbers Predict Humoral and Cellular Response Upon <scp>SARS</scp>â€‘ <scp>CoV</scp>â€‘2 Vaccination Among Patients Treated With Rituximab. <i>Arthritis and Rheumatology</i> , 2022, 74, 934-947.	5.6	55
78	Robust and durable serological response following pediatric SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 128.	12.8	54
79	Effect of functionalised fluorescence-labelled nanoparticles on mesenchymal stem cell differentiation. <i>Biomaterials</i> , 2010, 31, 2064-2071.	11.4	51
80	Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation. <i>Annals of Hematology</i> , 2012, 91, 1115-1120.	1.8	51
81	Comparative Analysis of Different Platelet Lysates and Platelet Rich Preparations to Stimulate Tendon Cell Biology: An In Vitro Study. <i>International Journal of Molecular Sciences</i> , 2018, 19, 212.	4.1	51
82	Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing. <i>Journal of Infectious Diseases</i> , 2021, 223, 796-801.	4.0	51
83	mRNAâ€‘Mediated Gene Delivery Into Human Progenitor Cells Promotes Highly Efficient Protein Expression. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 521-530.	3.6	48
84	Drug-induced agranulocytosis in the Berlin caseâ€‘control surveillance study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 339-345.	1.9	46
85	Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. <i>Leukemia and Lymphoma</i> , 2004, 45, 2387-2401.	1.3	42
86	The K+ channel openers diazoxide and NS1619 induce depolarization of mitochondria and have differential effects on cell Ca2+ in CD34+ cell line KG-1a. <i>Experimental Hematology</i> , 2003, 31, 815-823.	0.4	41
87	Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation. <i>Blood</i> , 2016, 128, 3169-3176.	1.4	41
88	Mitogenic activity of staphylococcal protein A is due to contaminating staphylococcal enterotoxins. <i>Journal of Immunological Methods</i> , 1987, 105, 133-137.	1.4	39
89	Crucial Role of IL1beta and C3a in the In Vitro-Response of Multipotent Mesenchymal Stromal Cells to Inflammatory Mediators of Polytrauma. <i>PLoS ONE</i> , 2015, 10, e0116772.	2.5	39
90	Thrombopoietin serum levels in patients with aplastic anaemia: correlation with platelet count and persistent elevation in remission. <i>British Journal of Haematology</i> , 1998, 100, 571-576.	2.5	37

#	ARTICLE	IF	CITATIONS
91	Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes. <i>Annals of Hematology</i> , 2011, 90, 887-899.	1.8	37
92	Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation. <i>Journal of Immunology</i> , 2016, 196, 866-876.	0.8	37
93	Fracture Healing Is Delayed in Immunodeficient NOD/scid β 2 μ gnull Mice. <i>PLoS ONE</i> , 2016, 11, e0147465	2.5	37
94	The power of DNA double-strand break (DSB) repair testing to predict breast cancer susceptibility. <i>FASEB Journal</i> , 2012, 26, 2094-2104.	0.5	36
95	Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation. <i>Journal of Clinical Investigation</i> , 2019, 129, 5123-5136.	8.2	36
96	Serum erythropoietin and serum transferrin receptor levels in aplastic anaemia. <i>British Journal of Haematology</i> , 1994, 88, 286-294.	2.5	35
97	S100A4 and Uric Acid Promote Mesenchymal Stromal Cell Induction of IL-10+/IDO+ Lymphocytes. <i>Journal of Immunology</i> , 2014, 192, 6102-6110.	0.8	35
98	An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection. <i>Antiviral Research</i> , 2020, 181, 104882.	4.1	34
99	Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1223-1231.	3.5	34
100	The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation. <i>Experimental Hematology</i> , 1999, 27, 1796-1805.	0.4	33
101	Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia. <i>Annals of Hematology</i> , 2002, 81, 566-569.	1.8	33
102	Translation of a standardized manufacturing protocol for mesenchymal stromal cells: A systematic comparison of validation and manufacturing data. <i>Cytotherapy</i> , 2019, 21, 468-482.	0.7	33
103	Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 1906-1917.	2.4	33
104	Altered increase in STAT1 expression and phosphorylation in severe COVID-19. <i>European Journal of Immunology</i> , 2022, 52, 138-148.	2.9	33
105	First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012. <i>American Journal of Hematology</i> , 2018, 93, 643-648.	4.1	32
106	Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomaterials to treat long bone non-unions. <i>Injury</i> , 2020, 51, S63-S73.	1.7	32
107	A phase I/II trial of recombinant human interleukin-6 in patients with aplastic anaemia. <i>British Journal of Haematology</i> , 1995, 90, 283-292.	2.5	31
108	Experimental blunt chest trauma-induced myocardial inflammation and alteration of gap-junction protein connexin 43. <i>PLoS ONE</i> , 2017, 12, e0187270.	2.5	31

#	ARTICLE	IF	CITATIONS
109	Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1. <i>Journal of Immunology</i> , 2019, 202, 2082-2094.	0.8	31
110	SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. <i>Eurosurveillance</i> , 2021, 26, .	7.0	31
111	Activation of human T lymphocytes III. Triggering of bystander cytotoxicity in cytotoxic T cell clones by antibodies against the T3 antigen or by a calcium ionophore. <i>European Journal of Immunology</i> , 1985, 15, 1019-1024.	2.9	30
112	Labeling of mesenchymal stromal cells with iron oxideâ€“poly(l-lactide) nanoparticles for magnetic resonance imaging: uptake, persistence, effects on cellular function and magnetic resonance imaging properties. <i>Cytotherapy</i> , 2011, 13, 962-975.	0.7	30
113	Paroxysmal Nocturnal Haemoglobinuria: A Replacement of Haematopoietic Tissue?. <i>Acta Haematologica</i> , 2000, 103, 41-48.	1.4	29
114	Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. <i>Immunobiology</i> , 2016, 221, 503-511.	1.9	28
115	HLA Matching in Unrelated Stem Cell Transplantation up to Date. <i>Transfusion Medicine and Hemotherapy</i> , 2019, 46, 326-336.	1.6	28
116	Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donorsâ€“A Retrospective Study. <i>PLoS ONE</i> , 2017, 12, e0169512.	2.5	28
117	Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition. <i>Haematologica</i> , 2017, 102, e499-e501.	3.5	26
118	The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemiaâ€“a report from the German Registry covering the period from 1998 to 2004. <i>Annals of Hematology</i> , 2009, 88, 1237-1247.	1.8	25
119	Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)â€“report on phases I and II. <i>Annals of Hematology</i> , 2017, 96, 171-181.	1.8	25
120	The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria.. <i>Blood</i> , 2006, 108, 123-123.	1.4	25
121	Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyteâ€“colonyâ€“stimulating factor: safety, efficacy, and graft performance. <i>Transfusion</i> , 2016, 56, 3055-3064.	1.6	24
122	One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096613.	2.5	24
123	Depolarisation of the plasma membrane in the arsenic trioxide (As2O3)-and anti-CD95-induced apoptosis in myeloid cells. <i>FEBS Letters</i> , 2004, 578, 85-89.	2.8	23
124	Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. <i>British Journal of Haematology</i> , 2010, 150, 377-379.	2.5	23
125	Drugs that inhibit complement. <i>Transfusion and Apheresis Science</i> , 2012, 46, 87-92.	1.0	23
126	Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19â€“Convalescent Donors. <i>Journal of Immunology</i> , 2021, 206, 2614-2622.	0.8	22

#	ARTICLE	IF	CITATIONS
127	Evaluation of platelet-rich plasma and hydrostatic pressure regarding cell differentiation in nucleus pulposus tissue engineering. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2013, 7, 244-252.	2.7	21
128	Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56brightCD16+NKp80+/-In-Vitro and Express KIR2DL2/DL3 and KIR3DL1. <i>Frontiers in Immunology</i> , 2021, 12, 640672.	4.8	21
129	Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies. <i>Transfusion Medicine and Hemotherapy</i> , 2021, 48, 137-147.	1.6	21
130	Endocrine Effects of Recombinant Interleukin 6 in Man. <i>Neuroendocrinology</i> , 1996, 63, 237-243.	2.5	20
131	Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system. <i>Annals of Hematology</i> , 2009, 88, 1047-1058.	1.8	20
132	Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. <i>International Journal of Cancer</i> , 2015, 137, 2083-2092.	5.1	19
133	Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. <i>Internal Medicine Journal</i> , 2017, 47, 1026-1034.	0.8	19
134	Osteonecrosis of the Femoral Head Safely Healed with Autologous, Expanded, Bone Marrow-Derived Mesenchymal Stromal Cells in a Multicentric Trial with Minimum 5 Years Follow-Up. <i>Journal of Clinical Medicine</i> , 2021, 10, 508.	2.4	19
135	Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH) – a report on phase III. <i>Annals of Hematology</i> , 2019, 98, 1547-1559.	1.8	18
136	Complement Activation and Organ Damage After Trauma – Differential Immune Response Based on Surgical Treatment Strategy. <i>Frontiers in Immunology</i> , 2020, 11, 64.	4.8	18
137	Tissue distribution of blood group membrane proteins beyond red cells: Evidence from cDNA libraries. <i>Transfusion and Apheresis Science</i> , 2006, 35, 71-82.	1.0	17
138	Direct and indirect effects of functionalised fluorescence-labelled nanoparticles on human osteoclast formation and activity. <i>Biomaterials</i> , 2011, 32, 1706-1714.	11.4	17
139	Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients. <i>Haematologica</i> , 2017, 102, 1947-1955.	3.5	17
140	Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1639.	4.8	17
141	Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry. <i>American Journal of Hematology</i> , 2019, 94, E37-E41.	4.1	17
142	Next-Generation Sequencing Technologies in Blood Group Typing. <i>Transfusion Medicine and Hemotherapy</i> , 2020, 47, 4-13.	1.6	17
143	Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary. <i>Vox Sanguinis</i> , 2021, 116, 493-496.	1.5	17
144	Complement Inhibition with Eculizumab in Patients with Cold Agglutinin Disease (CAD): Results from a Prospective Phase II Trial (DECADE Trial). <i>Blood</i> , 2015, 126, 274-274.	1.4	17

#	ARTICLE	IF	CITATIONS
145	Ecuzimab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria. <i>Expert Review of Hematology</i> , 2009, 2, 7-16.	2.2	16
146	Deregulated expression of circular RNAs in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1490-1503.	5.2	16
147	Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion: Clinical Improvement with Eculizumab Therapy.. <i>Blood</i> , 2007, 110, 840-840.	1.4	16
148	Serum Erythropoietin and Thrombopoietin Levels in Patients with Essential Thrombocythaemia. <i>Leukemia and Lymphoma</i> , 2000, 36, 533-538.	1.3	15
149	Effects of a Ceramic Biomaterial on Immune Modulatory Properties and Differentiation Potential of Human Mesenchymal Stromal Cells of Different Origin. <i>Tissue Engineering - Part A</i> , 2015, 21, 767-781.	3.1	15
150	Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients. <i>Haematologica</i> , 2017, 102, e76-e79.	3.5	15
151	Autologous Mesenchymal Stroma Cells Are Superior to Allogeneic Ones in Bone Defect Regeneration. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2526.	4.1	15
152	Inflammatory response of mesenchymal stromal cells after in vivo exposure with selected trauma-related factors and polytrauma serum. <i>PLoS ONE</i> , 2019, 14, e0216862.	2.5	15
153	Complement and the prothrombotic state. <i>Blood</i> , 2022, 139, 1954-1972.	1.4	15
154	DNA methylation in <i>PRDM8</i> is indicative for dyskeratosis congenita. <i>Oncotarget</i> , 2016, 7, 10765-10772.	1.8	15
155	Depolarization of Mitochondria and Activation of Caspases Are Common Features of Arsenic(III)-Induced Apoptosis in Myelogenic and Lymphatic Cell Lines. <i>Chemical Research in Toxicology</i> , 2004, 17, 119-128.	3.3	14
156	Large-Scale Screening of HCMV-Seropositive Blood Donors Indicates that HCMV Effectively Escapes from Antibodies by Cell-Associated Spread. <i>Viruses</i> , 2018, 10, 500.	3.3	14
157	A Possible Role for Thrombopoietin and Its Receptor c-mpl in the Pathobiology of Essential Thrombocythemia. <i>Seminars in Thrombosis and Hemostasis</i> , 1997, 23, 419-423.	2.7	13
158	B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21. <i>International Immunology</i> , 2014, 26, 383-395.	4.0	13
159	Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses. <i>Theranostics</i> , 2017, 7, 1705-1718.	10.0	13
160	Osteoarthritic Milieu Affects Adipose-Derived Mesenchymal Stromal Cells. <i>Journal of Orthopaedic Research</i> , 2020, 38, 336-347.	2.3	13
161	The role of mitochondrial targeting in arsenic trioxide-induced apoptosis in myeloid cell lines. <i>British Journal of Haematology</i> , 2004, 124, 186-189.	2.5	12
162	Systemic and Cardiac Alterations After Long Bone Fracture. <i>Shock</i> , 2020, 54, 761-773.	2.1	12

#	ARTICLE	IF	CITATIONS
163	Outcome of Patients with Aplastic Anemia Given First Line Transplantation or Immunosuppression in the Last Decade: A Report from European Group for Blood and Marrow Transplantation (EBMT).. <i>Blood</i> , 2006, 108, 52-52.	1.4	12
164	Congenital CD59 Deficiency. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 495-507.	2.2	11
165	International Forum on GMP-grade human platelet lysate for cell propagation. <i>Vox Sanguinis</i> , 2018, 113, e1-e25.	1.5	11
166	ATP promotes immunosuppressive capacities of mesenchymal stromal cells by enhancing the expression of indoleamine dioxygenase. <i>Immunity, Inflammation and Disease</i> , 2018, 6, 448-455.	2.7	11
167	Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 629-640.	4.2	11
168	Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial. <i>Haematologica</i> , 2021, 106, 1086-1096.	3.5	11
169	HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 771449.	4.8	11
170	The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis. <i>Frontiers in Immunology</i> , 2020, 11, 614976.	4.8	10
171	BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. <i>Frontiers in Immunology</i> , 2021, 12, 743422.	4.8	10
172	Arsenic trioxide-induced apoptosis is independent of CD95 in lymphatic cell lines. <i>Oncology Reports</i> , 2004, 11, 509-13.	2.6	10
173	The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210910.	2.5	10
174	Antibodies to glycosylphosphatidyl-inositol anchored proteins (GPI-AP) in antithymocyte and antilymphocyte globulin: possible role for the expansion of GPI-AP deficient cells in aplastic anemia. <i>Annals of Hematology</i> , 2009, 88, 889-895.	1.8	9
175	Systemic recovery and therapeutic effects of transplanted allogenic and xenogenic mesenchymal stromal cells in a rat blunt chest trauma model. <i>Cytotherapy</i> , 2018, 20, 218-231.	0.7	9
176	Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2357-2365.	2.0	9
177	Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces. <i>Frontiers in Immunology</i> , 2021, 12, 615748.	4.8	9
178	Terminal Complement Inhibitor Eculizumab Improves Complement-Mediated Platelet Consumption and Thrombocytopenia in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).. <i>Blood</i> , 2009, 114, 4030-4030.	1.4	9
179	HIV-Infected T Cells Induce Granzyme B-Secreting Regulatory B Cells in An Interleukin 21-Dependent Fashion,. <i>Blood</i> , 2011, 118, 3222-3222.	1.4	9
180	Clinically Important Difference for the FACIT-Fatigue Scale in Paroxysmal Nocturnal Hemoglobinuria: A Derivation from International PNH Registry Patient Data. <i>Blood</i> , 2021, 138, 1952-1952.	1.4	9

#	ARTICLE	IF	CITATIONS
181	Desmoplakin and KIF20B as target antigens in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2010, 151, 273-280.	2.5	8
182	Identification of Elite Neutralizers With Broad and Potent Neutralizing Activity Against Human Cytomegalovirus (HCMV) in a Population of HCMV-Seropositive Blood Donors. <i>Journal of Infectious Diseases</i> , 2018, 218, 876-885.	4.0	8
183	The Monoclonal Anti-CD157 Antibody Clone SY11B5, Used for High Sensitivity Detection of PNH Clones on WBCs, Fails to Detect a Common Polymorphic Variant Encoded by <i>CD157</i> . <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 652-659.	1.5	8
184	Subcutaneous Alemtuzumab Is a Safe and Effective Treatment for Global or Single-Lineage Immune-Mediated Marrow Failures: a Survey from the EBMT-WPSAA. <i>Blood</i> , 2008, 112, 1042-1042.	1.4	8
185	Constitutional PIGA mutations cause a novel subtype of hemochromatosis in patients with neurologic dysfunction. <i>Blood</i> , 2022, 139, 1418-1422.	1.4	8
186	Hepcidin/Ferritin Quotient Helps to Predict Spontaneous Recovery from Iron Loss following Blood Donation. <i>Transfusion Medicine and Hemotherapy</i> , 2015, 42, 390-395.	1.6	7
187	Gender, cholinesterase, platelet count and red cell count are main predictors of peripheral blood stem cell mobilization in healthy donors. <i>Vox Sanguinis</i> , 2019, 114, 275-282.	1.5	7
188	Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies. <i>Blood</i> , 2019, 134, 952-952.	1.4	7
189	B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients. <i>Frontiers in Immunology</i> , 2022, 13, 822885.	4.8	7
190	Evidence for a paracrine pathway of B-cell stimulation in hairy cell leukaemia. <i>British Journal of Haematology</i> , 1995, 90, 156-162.	2.5	6
191	HLA-Matched Sibling Transplantation for Severe Aplastic Anemia: Impact of HLA DR15 Antigen Status on Engraftment, Graft-versus-Host Disease, and Overall Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1401-1406.	2.0	6
192	Immunosuppressive therapy for transplant-ineligible aplastic anemia patients. <i>Expert Review of Hematology</i> , 2015, 8, 89-99.	2.2	6
193	Use of Blood Transfusions In Paroxysmal Nocturnal Hemoglobinuria Patients with and without Aplastic Anemia Enrolled In the Global PNH Registry. <i>Blood</i> , 2010, 116, 2241-2241.	1.4	6
194	Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 241-247.	3.5	5
195	Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay. <i>Transfusion</i> , 2018, 58, 2992-3002.	1.6	5
196	Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects. <i>Haematologica</i> , 2018, 103, 1527-1534.	3.5	5
197	Validation of Microbiological Testing of Cellular Medicinal Products Containing Antibiotics. <i>Transfusion Medicine and Hemotherapy</i> , 2020, 47, 144-151.	1.6	5
198	<i>HLA-DRB4*01:14</i> is a null allele, and renamed <i>HLA-DRB4*01:14N</i> . <i>Hla</i> , 2020, 95, 73-75.	0.6	5

#	ARTICLE	IF	CITATIONS
199	Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study.. Blood, 2006, 108, 971-971.	1.4	5
200	Evaluation of Paroxysmal Nocturnal Hemoglobinuria Disease Burden: The Patient's Perspective. A Report From the International PNH Registry.. Blood, 2010, 116, 1525-1525.	1.4	5
201	Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation. Haematologica, 2017, 102, 796-803.	3.5	4
202	A novel allele of the atypical chemokine receptor 1 (ACKR1) gene containing the nucleotide change c.126 T>G (p.42Glu) encodes a third Duffy blood group protein sequence antithetical to that encoding Fya and Fyb antigens. Transfusion, 2019, 59, 2158-2159.	1.6	4
203	Granulocyte transfusions â€“ bridging to allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2020, 61, 481-484.	1.3	4
204	Effects of Circulating HMGB-1 and Histones on Cardiomyocytesâ€“ Hemadsorption of These DAMPs as Therapeutic Strategy after Multiple Trauma. Journal of Clinical Medicine, 2020, 9, 1421.	2.4	4
205	A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2018, 132, 2330-2330.	1.4	4
206	Use of G-CSF in Patients with Severe Aplastic Anemia Treated with ATG and Cyclosporine Increases Neutrophils and Decreases Infection Rates and Hospitalization Days but Does Not Improve Long-Term Outcome: Results of a Prospective, Randomized Clinical Trial of the EBMT.. Blood, 2009, 114, 496-496.	1.4	4
207	Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2010, 116, 4237-4237.	1.4	4
208	Erytra blood group analyser and kode technology testing of SARSâ€“CoVâ€“2 antibodies among convalescent patients and vaccinated individuals. EJHaem, 2022, 3, 72-79.	1.0	4
209	Predictors for Improvement in Patient-Reported Outcomes: <i>Post-Hoc</i> Analysis of a Phase 3 Randomized, Open-Label Study of Eculizumab and Ravulizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2021, 138, 2196-2196.	1.4	4
210	Upregulation of Checkpoint Ligand Programmed Death-Ligand 1 in Patients with Paroxysmal Nocturnal Hemoglobinuria Explained by Proximal Complement Activation. Journal of Immunology, 2022, 208, 1248-1258.	0.8	4
211	BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages. Frontiers in Immunology, 0, 13, .	4.8	4
212	Higher risk for chronic graftâ€“versusâ€“host disease (<sc>GvHD</sc>) in <sc>HLAâ€“</sc> mismatched transplants following allogeneic hematopoietic stem cell transplantation â€“ a retrospective study. Hla, 0, , .	0.6	4
213	Increased requirement for platelet transfusions concurrent with enhanced bleeding during romiplostim treatment in a patient with thrombocytopenia due to bone marrow failure. Annals of Hematology, 2011, 90, 1357-1359.	1.8	3
214	A Novel Tissue and Stem Cell Specific TERF1 Splice Variant Is Downregulated in Tumour Cells. International Journal of Molecular Sciences, 2020, 21, 85.	4.1	3
215	Extended loci histocompatibility matching in HSCTâ€“Going beyond classical HLA. International Journal of Immunogenetics, 2021, 48, 299-316.	1.8	3
216	Efficacy of Eculizumab in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria in the International PNH Registry. Blood, 2018, 132, 3614-3614.	1.4	3

#	ARTICLE	IF	CITATIONS
217	Frequency and Stimulation of NPM1-Specific Immune Responses By Anti-PD1 Antibodies in NPM1-Mutated AML. <i>Blood</i> , 2020, 136, 15-15.	1.4	3
218	Effects of Eculizumab Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Concurrent Immunosuppressive Therapy for Bone Marrow Insufficiency.. <i>Blood</i> , 2009, 114, 3012-3012.	1.4	3
219	Granzyme B Is a Key Regulator of Plasmacytoid Dendritic Cell Immunogenicity. <i>Blood</i> , 2014, 124, 4127-4127.	1.4	3
220	Integration of Hi-C and Nanopore Sequencing for Structural Variant Analysis in AML with a Complex Karyotype: (Chromothripsis)Å². <i>Blood</i> , 2020, 136, 28-28.	1.4	3
221	Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: <scp>Realâ€world</scp> findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry. <i>European Journal of Haematology</i> , 2022, 109, 197-204.	2.2	3
222	Empfehlungen zur Diagnostik der Paroxysmalen nÃchtlichen HÃmoglobinurie: deutsch â€“ Åsterreichischer Konsensus/Recommendations for the diagnosis of paroxysmal nocturnal hemoglobinuria: a German-Austrian consensus. <i>Laboratoriums Medizin</i> , 2011, 35, 315-327.	0.6	2
223	CD90 Is Dispensable for White and Beige/Brown Adipocyte Differentiation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7907.	4.1	2
224	Matched Sibling Transplants for Aplastic Anemia: Survival Advantage for Marrow Vs Peripheral Blood Transplants, In All Age groups. <i>Blood</i> , 2010, 116, 523-523.	1.4	2
225	Clinical Characteristics of Classic Paroxysmal Nocturnal Hemoglobinuria (PNH) in Pediatric Patients: A Comparison with Classic PNH in Adults. An International PNH Registry Study. <i>Blood</i> , 2011, 118, 2102-2102.	1.4	2
226	Development Of a Disease Specific Quality Of Life Questionnaire For Patients With Aplastic Anemia and/Or Paroxysmal Nocturnal Hemoglobinuria (QLQ-AA/PNH). <i>Blood</i> , 2013, 122, 1680-1680.	1.4	2
227	Eculizumab Treatment Improves Outcomes of Pregnancy in Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2014, 124, 4393-4393.	1.4	2
228	Specific Immune Responses for Leukemia-Associated Antigens Against Myeloid Leukemic Cells Are Increased By Immune Checkpoint Inhibition. <i>Blood</i> , 2016, 128, 4054-4054.	1.4	2
229	An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial. <i>Blood</i> , 2020, 136, 2-3.	1.4	2
230	Successful treatment of partial graft failure after matched unrelated donor stem cell transplantation by a combination of ancestim (stem cell factor) and granulocyte colony stimulating factor in a patient with heavily pre-treated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 2015-2017.	1.3	1
231	Absence of CC chemokine receptors 2a and 2b from human adipose lineage cells. <i>Molecular and Cellular Endocrinology</i> , 2013, 369, 72-85.	3.2	1
232	Response to Comment on â€œSelf versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1â€• <i>Journal of Immunology</i> , 2019, 203, 2029.2-2030.	0.8	1
233	Expression of PD-L1 in Leukemic Progenitor Cells Defines NPM1 Mutated AML As a Potential Subgroup for PD1/PD-L1 Directed Immunotherapy. <i>Blood</i> , 2018, 132, 2734-2734.	1.4	1
234	Hematopoietic Recovery and Overall Survival after HLA-Matched Sibling Transplants for Older Patients with Severe Aplastic Anemia (SAA).. <i>Blood</i> , 2008, 112, 2169-2169.	1.4	1

#	ARTICLE	IF	CITATIONS
235	Direct Antiglobulin Test, Ferritin and GPI-Negative Cell Populations in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Eculizumab Therapy: Extravascular Hemolysis Unmasked by Efficient Eculizumab-Mediated Inhibition of Intravascular Hemolysis.. Blood, 2008, 112, 3440-3440.	1.4	1
236	Shift to a New Donor Does Not Improve the Outcome After Second Allogeneic Stem Cell Transplantation (alloSCT) in Acute Leukemia Relapse After a First Allosct – a Risk Factor Analysis by the German Stem Cell Registry (DRST).. Blood, 2009, 114, 3328-3328.	1.4	1
237	GMP-Grade Large-Scale Expansion of Bone-Marrow- (BM) Derived Human Mesenchymal Stem/Stroma Cells (MSC): Comparison of Efficacy of Different Expansion Systems and Role of Cytokines/Chemokines. Blood, 2010, 116, 337-337.	1.4	1
238	Allogeneic Hematopoietic Stem Cell Transplantation in Paroxysmal Nocturnal Hemoglobinuria: A Transplant Versus No Transplant Matched Comparison Study On Behalf of the Severe Aplastic Anemia Working Party (SAA WP) of the European Group for Blood and Marrow Transplantation (EBMT) Group and the French Society of Hematology (SFH). Blood, 2011, 118, 2403-2403.	1.4	1
239	Therapy of Acquired Aplastic Anemia (AA) with Rabbit Antithymocyte Globulin (rATG): A Retrospective Analysis by the Working Group on Non-Malignant Disorders of Hematopoiesis of the German Society of Hematology and Oncology (DGHO).. Blood, 2011, 118, 3434-3434.	1.4	1
240	Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2012, 120, 1260-1260.	1.4	1
241	Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: An on Going Joint Study of the AAWP EBMT Group and the French Society of Hematology. Blood, 2008, 112, 3442-3442.	1.4	1
242	The Presence of HLA DR15 Antigen in Patients with Severe Aplastic Anemia Does Not Impact Engraftment and Survival After HLA-Identical Sibling Transplantation.. Blood, 2009, 114, 2280-2280.	1.4	1
243	Prospective Phase II Pilot Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline) with Ciclosporin for Patients with Acquired Aplastic Anemia and Matched Pair Analysis with Patients Treated with Horse ATG (Lymphoglobuline) and Ciclosporin: A Study From the EBMT Severe Aplastic Anemia Working Party (RATGAA07). Blood, 2011, 118, 2408-2408.	1.4	1
244	Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks. Blood, 2020, 136, 37-38.	1.4	1
245	COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2020, 136, 6-7.	1.4	1
246	Corrigendum to: Depolarisation of the plasma membrane in the arsenic trioxide (As ₂ O ₃)- and anti-CD95-induced apoptosis in myeloid cells (FEBS 29005) [FEBS Letters 578 (2004) 85-89]. FEBS Letters, 2005, 579, 3866-3866.	2.8	0
247	98-P. Human Immunology, 2012, 73, 113.	2.4	0
248	Laboratory examination of hematologic diseases at the interdisciplinary hematologic competence center (IHK) of Innsbruck of the clinic for hemato-oncology V of the university hospital Innsbruck 2013, 37, .	0.6	0
249	Paroxysmal nocturnal hemoglobinuria revisited: news on pathophysiology, clinical course and treatment. Laboratoriums Medizin, 2015, 39, 87-96.	0.6	0
250	Bone Marrow Failure in PNH. , 2017, , 137-151.		0
251	P043 HLA-DPB matching and donor cytomegalovirus positive (CMV+) status: An –unconventional alliance– associated with a decreased relapse incidence in unrelated hematopoietic stem cell transplantation (UHSCT). Human Immunology, 2017, 78, 86.	2.4	0
252	Proaerolysin Multi Color Flow-Fish Reveals Shortened Telomere Length in GPI ⁺ as Compared to GPI ⁺ Granulocytes from Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).. Blood, 2004, 104, 171-171.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Highly Efficient mRNA- and cDNA-Based Transient Gene Delivery into Human Progenitor Cells.. Blood, 2006, 108, 5471-5471.	1.4	0
254	Unrelated Donor Transplants for Severe Aplastic Anemia: A Report from the EBMT SAA Working Party.. Blood, 2007, 110, 3054-3054.	1.4	0
255	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Related Donor in Chronic Myeloid Leukemia (CML): An Explanation for Fast Improvement of Survival in Two Consecutive German CML Studies.. Blood, 2009, 114, 3281-3281.	1.4	0
256	A Global Registry of Patients with Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2009, 114, 3007-3007.	1.4	0
257	Allogeneic Stem Cell Transplantation for Acquired Aplastic Anemia: Better Outcome with Bone Marrow as Compared to Peripheral Blood in HLA-Matched Sibling Donor Transplantation and Improved Outcome Over Time After Matched Unrelated Donor Transplantation. A Retrospective Analysis of Transplants Reported to the German Registry for Stem Cell Transplantation (DRST).. Blood, 2009, 114, 876-876.	1.4	0
258	Telomere Elongation In Vivo and Clinical Response Upon Androgen Treatment in a Patient with Aplastic Anemia and a Heterozygous hTERT Gene Mutation,. Blood, 2011, 118, 3427-3427.	1.4	0
259	Quality Controls of Immune Regulatory Properties of Ex-Vivo, GMP-Grade Expanded Mesenchymal Stromal Cells for Clinical Use (European multicenter study CASCADE).. Blood, 2011, 118, 4049-4049.	1.4	0
260	Shared and Divergent Stimulatory Effects of S100A4 and Uric Acid on Proliferation and Chemotaxis of Mesenchymal Stem Cells (MSCs). Interplay Between Necrotic Tumor Material and Immunosuppressive MSCs within Tumor Microenvironment,. Blood, 2011, 118, 3239-3239.	1.4	0
261	Recommendations for the diagnosis of paroxysmal nocturnal hemoglobinuria: a German-Austrian	0.6	0
262	HIV Triggers Interleukin 21-Mediated Induction of Granzyme B-Secreting B Cells with Regulatory and Antiviral Potential. Blood, 2012, 120, 1042-1042.	1.4	0
263	Eculizumab Protects Against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study. Blood, 2012, 120, 3480-3480.	1.4	0
264	Interleukin-21-Induced Granzyme B-Expressing B Lymphocytes Infiltrate Tumors and Regulate T Cells. Blood, 2012, 120, 3278-3278.	1.4	0
265	Outcome of Aplastic Anemia in Children. A Survey On Behalf of the SAA and PDWP of the EBMT. Blood, 2012, 120, 643-643.	1.4	0
266	Analysis Of Leukemic Stem Cell Population Comparing NPM1wt and NPM1mut AML Patients and Potential Therapeutic Targets. Blood, 2013, 122, 2624-2624.	1.4	0
267	Effects Of a Novel Ceramic Biomaterial On Immune Modulatory Properties and Differentiation Potential Of Mesenchymal Stromal Cells. Blood, 2013, 122, 4858-4858.	1.4	0
268	Quality Controls Of Immune Regulatory Properties Of Ex-Vivo, GMP-Grade Expanded Mesenchymal Stromal Cells For Clinical Use. Blood, 2013, 122, 5413-5413.	1.4	0
269	Outcome Of Aplastic Anemia In Adolescence. A Survey Of The Severe Aplastic Anemia Working Party (SAAWP) Of The European Blood and Bone Marrow Transplant Group (EBMT). Blood, 2013, 122, 2481-2481.	1.4	0
270	CD27+IgDâ€“ B cells in the peripheral blood of colorectal cancer patients: on anti-tumor or tumor-protective mission?. Oncoscience, 2014, 1, 558-559.	2.2	0

#	ARTICLE	IF	CITATIONS
271	Similar Outcome of Upfront Unrelated and Matched Sibling Donor Hematopoietic Stem Cell Transplantation in Idiopathic Aplastic Anaemia of Childhood and Adolescence: A Cohort Controlled Study on Behalf of the UK Paediatric BMT WP, of the PD WP and of the SAA WP of the EBMT. <i>Blood</i> , 2014, 124, 256-256.	1.4	0
272	IL-21-Mediated Generation of Human Regulatory B Cells Occurs Independently of CD40 Signaling. <i>Blood</i> , 2014, 124, 1413-1413.	1.4	0
273	Clinical Benefit of Eculizumab in Patients with No Transfusion History in the International Paroxysmal Nocturnal Hemoglobinuria Registry. <i>Blood</i> , 2015, 126, 3340-3340.	1.4	0
274	Peptide Vaccination Against Cytomegalovirus (CMV) Elicits Immunological and Clinical Responses after Allogeneic Stem Cell Transplantation Even from a CMV Seronegative Donor. <i>Blood</i> , 2016, 128, 2519-2519.	1.4	0
275	Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT. <i>Blood</i> , 2018, 132, 1307-1307.	1.4	0
276	The Role of HLA-E Polymorphism in Acute Leukemia Patients Receiving a 10/10 HLA Matched Unrelated HSCT. <i>Blood</i> , 2018, 132, 310-310.	1.4	0
277	Donor Genetic Determinant of Thymopoiesis rs2204985 Impacts Clinical Outcome after Single HLA Mismatched HSCT. <i>Blood</i> , 2021, 138, 3903-3903.	1.4	0
278	Transfusion Requirements in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria with or without a History of Bone Marrow Disorder Receiving Ravulizumab and Eculizumab: Results from a Phase 3 Non-Inferiority Study Extension. <i>Blood</i> , 2020, 136, 31-33.	1.4	0
279	Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies. <i>Blood</i> , 2020, 136, 42-43.	1.4	0